TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04088760
Drug: TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The majority of TCRαβ+ T cells and CD19+ B cells will be removed from the allogeneic graft utilizing the CliniMACS® immunomagnetic selection device (Miltenyi Biotec). The depletion process involves two phases; cell labeling (phase 1) and the automated immunomagnetic depletion process (phase 2). The CD34+ dose may be adjusted by the need to not exceed the TCRαβ+CD3+ dose threshold.
Study: NCT04258865
Drug: CKD-828, D097, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT00193037
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal Doxorubicin
Study: NCT03748082
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.
Study: NCT00908778
Drug: Vitreosolve
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravitreal injection
Study: NCT04353791
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01391793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily for 3 days
Study: NCT02962076
Drug: [C-11] Meta-hydroxyephedrine radioactive tracer (MHED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: this tracer detects the distribution of sympathetic nerve fibers in the left ventricle
Study: NCT00390065
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early low dose (5ppm) NO inhalation Placebo
Study: NCT01666730
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01666730
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02296320
Drug: MEDI4893
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single IV dose of MEDI4893 2000 or 5000 mg on Day 1 of the study.
Study: NCT03006445
Drug: FYU-981
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01184391
Drug: DEPAKOTE® Tablets, 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 500 mg tablet, under fasting conditions
Study: NCT01577121
Drug: indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg / 6 hours during 5 days
Study: NCT01735630
Drug: ELND005
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01735630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01577121
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg / 6 hours during 5 days
Study: NCT00172055
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01522664
Drug: DEDN6526A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses
Study: NCT01104766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Study: NCT02588677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00660647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline injection 0.9%, 0.8 ml s.c. every second week up to 2 years
Study: NCT01214226
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: prolonged-release tablets 3 time per day for 1 month
Study: NCT02359305
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen given by IV
Study: NCT02359305
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen suppository given rectally
Study: NCT01233505
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03428022
Drug: Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
Study: NCT00211848
Drug: Polyenylphosphatidylcholine (PPC)
Normalized name: lysophosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06309732
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Doses are titrated against renal function. Dosage: 30 mins loading plus 12 hour infusion
Study: NCT01221792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non active comparator
Study: NCT01864655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given to placebo group
Study: NCT04292483
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled vasodilator to increase pulmonary capillary perfusion
Study: NCT00229593
Drug: Testosterone Gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg Testosterone gel daily for 3 weeks
Study: NCT00025363
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00025363
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00334958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 placebo tablets twice daily.
Study: NCT03773263
Drug: sequential IVM system
Approvals — FDA: no, EMA: no, PMDA: no
Description: The immature oocytes will be cultured in sequential oocyte IVM medium 1 for 6 hours (37℃, 5% CO2). After flushed 3 times, COCs were removed into sequential oocyte IVM medium 2 for further cultivation.
Study: NCT01389388
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All the patients who have signed the informed consent will after they have had performed a MCT and possibly SCC with an IVUS, will be give Rosuvastatinuntill their LDL level has reached 1.6-1.8 mmol/l. The objective is that all the participants should have reached 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
Study: NCT04350580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride 0.9% in the same volume and over the same time as the immunoglobulin
Study: NCT03716427
Drug: CT1812
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00048126
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg po bid
Study: NCT02567968
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg). The time to wake will be measured.
Study: NCT02567968
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetized volunteers will be allowed to wake after injection of saline (placebo control). The time to wake will be measured.
Study: NCT01924078
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: metronomic use: capecitabine 500mg/tid
Study: NCT01533077
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of BIA 9-1067 (single-dose)
Study: NCT01533077
Drug: Sinemet® 100/25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: immediate-release levodopa/carbidopa 100/25 (single-dose).
Study: NCT01924078
Drug: aromatase Inhibitors (AIs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.
Study: NCT02702817
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pale blue oval tablets
Study: NCT00167648
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol patches, six at 0.1 mg each, changed every 3-4 days
Study: NCT02702817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pale blue oval tablets with no active ingredients, identical in appearance to naproxen intervention
Study: NCT00807170
Drug: ZD6474
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg as a once daily oral dose, 21 days
Study: NCT00807170
Drug: ZD6474
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg as a once daily oral dose, 21 days
Study: NCT00376337
Drug: Systemic antifungal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT01395030
Drug: 18F-fluoromethylcholine
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo FCH PET/CT
Study: NCT03574857
Drug: Chlorothiazide Injection
Normalized name: chlorothiazide Injection
DrugBank: Chlorothiazide (DB00880)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1: Chlorothiazide 500 mg IV Day 2: Chlorothiazide 500 mg IV
Study: NCT02079766
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: 370 megabecquerel (MBq) IV single-dose
Study: NCT00113022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive equivalent of 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
Study: NCT01355081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine placebo
Study: NCT03629249
Drug: Placebo once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 150 mg and one tablet blinded placebo to QAW039 450 mg).
Study: NCT03629249
Drug: QAW039 150 mg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAW039 150 mg once daily (one tablet of blinded QAW039 150 mg to be given together with one tablet blinded placebo to QAW039 450 mg)
Study: NCT03629249
Drug: QAW039 450 mg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAW039 450 mg once daily (one tablet of blinded QAW039 450 mg to be given together with one tablet blinded placebo to QAW039 150 mg)
Study: NCT00276757
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00276757
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00276757
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03096821
Drug: ngFDS selected treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment based on next-generation functional drug screening (ngFDS). Treatment with commercially available treatments (per package insert instructions) selected by functional drug screening. For drug screening tumor cells from bone marrow aspirates, peripheral blood, pleural effusion, or excised lymph node samples are purified over Ficoll gradient (bone marrow, peripheral blood, pleural effusion) (GE healthcare) or homogenized and filtered (lymph tissue).
Study: NCT01597401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.
Study: NCT01938482
Drug: 0.3% GSK1940029 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be supplied as gel for topical application
Study: NCT01938482
Drug: 1% GSK1940029 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be supplied as gel for topical application
Study: NCT01938482
Drug: 0.3%/1% vehicle gel only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be supplied as gel for topical application
Study: NCT01790568
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01621165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
Study: NCT05086848
Drug: Irinotecan liposome、5-fluorouracil、Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan liposome、5-fluorouracil、Leucovorin
Study: NCT00545402
Drug: Mycophenolate mofetil, adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d PO BID during meals from Day 0 to Day 4, followed by dose adjustment based on AUC using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12.
Study: NCT03095222
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care for pain management.
Study: NCT00545402
Drug: Corticosteroids, IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-15 mg/kg IV pre-operation on Day 0
Study: NCT00545402
Drug: Mycophenolate mofetil, Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/d PO BID during meals from Day 0 to Month 12
Study: NCT00545402
Drug: Corticosteroids, PO
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d QDS from Day 0 through Month 1; 15 mg/day, TID from the end of Month 1 through Month 2; 10 mg/d BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
Study: NCT01806805
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00074854
Drug: CP-547,632
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01624259
Drug: LY2189265
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02237781
Drug: Gonadotropins
Normalized name: GONADOTROPINS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH will depend on the levels of E2 and FSH prior to ovarian stimulation .
Study: NCT00314353
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 850 mg/m2 po BID Days 1-14 every 21 days for eight cycles\*#~\*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.~#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID
Study: NCT01362361
Drug: mFOLFOX6 + BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 + BIBF1120 (2x200 mg/d d1-d14) (repeated every 14 days)
Study: NCT01362361
Drug: mFOLFOX6+placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 + placebo (2x200 mg/d d1-d14) (repeated every 14 days)
Study: NCT00577109
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/m2 iv on day 1 of each 2 week cycle
Study: NCT00577109
Drug: 5 FU
Normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg/m2 iv on day 1 of each 2 week cycle
Study: NCT02726971
Drug: Femoston
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.
Study: NCT03255148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray
Study: NCT00145522
Drug: 17ß-Estradiol/Dydrogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/5 mg/day for 12 cycles of 28 days
Study: NCT03372850
Drug: HIP1601
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Drug
Study: NCT03372850
Drug: HGP1705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference Drug
Study: NCT04076254
Drug: Albumins
Normalized name: lactalbumins, hydrolyzates
Approvals — FDA: no, EMA: no, PMDA: no
Description: albumin 5%
Study: NCT03555916
Drug: BOTOX®, Allergan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 U BTX-A (BOTOX®, Allergan) powder diluted in 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
Study: NCT03555916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
Study: NCT01817907
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a sugar pill during the placebo arm
Study: NCT03420079
Drug: FCN-411 Dose-escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: * FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~* FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR.
Study: NCT02465983
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single dose of chemotherapy to be administered prior to dosing of the CART-meso-19 cells
Study: NCT02216071
Drug: EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension
Normalized name: Otocort Sterile Suspension Otic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
Study: NCT03161288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT01817283
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills produced the same as Triptolide wilfordii.
Study: NCT00622284
Drug: Placebo identical to BI 1356 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily
Study: NCT01717287
Drug: Other Anti-Retroviral Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing
Study: NCT02242201
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection, weight-based dosage of 100 mcg - 300 mcg
Study: NCT02242201
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection, 30 mg
Study: NCT00556127
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg/m2 on day 3
Study: NCT00282984
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg placebo twice daily by mouth for 12 weeks
Study: NCT01587378
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical placebo tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
Study: NCT02146742
Drug: ASP1707
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02146742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00912353
Drug: AZD7268
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Oral
Study: NCT00912353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Oral
Study: NCT00190671
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
Study: NCT04205201
Drug: Drugs, Investigational
Approvals — FDA: no, EMA: no, PMDA: no
Description: To see the safety and efficacy of topical latanoprost compared with topical brimonidine in the treatment of the primary open angle
Study: NCT00454896
Drug: VESIcare®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00454896
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03926130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03926130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03583333
Drug: IMI/REL FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Imipenem, 500 mg Cilastatin and 250 mg Relebactam powder FDC provided in a single vial
Study: NCT03583333
Drug: PIP/TAZ FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 mg Piperacillin and 500 mg Tazobactam powder FDC provided in a single vial
Study: NCT01513070
Drug: Quick-Acting Heart Reliever
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quick-Acting Heart Reliever，200mg，tid，po. for six months
Study: NCT01187966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no